A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.
New drug applications approved by US FDA as of 16 - 31 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
There is a high prevalence of metabolic syndrome (MetS) in patients with psoriasis in Singapore, which is nearly threefold higher than the general population, a study has shown. However, no association exists between disease severity and presence of MetS.
The new first-in-class monoclonal antibody dupilumab (Dupixent®, Sanofi) is now available in Malaysia. The agent is indicated for use in adults with moderate-to-severe atopic dermatitis (AD), whose disease is not adequately controlled by topical therapies or when those therapies are contraindicated.
Disease severity, rather than sociodemographic factors, is the strongest determinant of health-related quality of life (HRQOL) in children with atopic dermatitis and their caregivers, according to a recent Singapore study.
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A dermatology outpatient setting in Singapore has seen a moderately high prevalence of steroid phobia, with gender differences for topical corticosteroids (TCS) phobia, according to a study. Misconceptions also exist regarding the side effects of steroids.
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.